News
The 12-month price targets, analyzed by analysts, offer insights with an average target of $41.75, a high estimate of $49.00, ...
Argentina's lifting of currency controls has boosted investor confidence, as reflected in ARGT's 3.5% jump, outperforming ...
Artelo Biosciences advances ART26.12 for psoriasis and CIPN, while ART27.13 shows early promise in cancer-related anorexia ...
Kansas farmers turn to sorghum as China cancels purchases due to trade war. Grain being rebranded as superfood, gaining ...
Airbus will acquire Spirit Aerosystems' assets in multiple locations globally, including facilities in North Carolina and ...
Granted, the bullish narrative on China — especially its previously skyrocketing internet technology industry — presents ...
A record-high percentage of U.S. households are making only minimum payments on their credit cards, according to new data ...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a ...
Social Security claims rose due to fearmongering, budget cuts and administrative turmoil. Early claims lead to lower payments ...
A man with ALS received a Neuralink BCI implant, allowing him to control a laptop cursor and generate his own voice using AI.
Ace investor and fund manager, Cathie Wood, is doubling down on Palantir Technologies Inc. (NASDAQ: PLTR), reaffirming her ...
Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop
Revvity posts strong Q1 results with Life Sciences and Diagnostics growth, lifts 2025 sales guidance, and expects higher adjusted operating margins.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results